Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements (mechanism, dosing format/regimens, inclusion of MMD as an endpoint, adult/pediatric indication scope) are supported by the provided label excerpts. However, multiple claims go beyond label support or conflict with how the label frames evidence (e.g., comparing to placebo and generalizing response/timing without label support) and the label excerpts provided do not support statements about switching/adding other preventives or that common side effects include injection-site reactions.
Category Scores
Accurate Statements
Ajovy targets CGRP (calcitonin gene-related peptide).
12.1 Mechanism of Action: "Fremanezumab-vfrm... binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor."
By blocking CGRP, Ajovy can reduce how often migraines happen for many people who use it for prevention.
12.1 Mechanism of Action (blocks CGRP ligand binding) and 14 Clinical Studies (statistically significant improvements on migraine endpoints vs placebo in adult/pediatric studies).
Ajovy is administered as a preventive injection on a monthly or every three months regimen, depending on the regimen prescribed by a clinician.
2.1 Recommended Dosage (adults: "225 mg monthly" or "675 mg every 3 months (quarterly)"; pediatric 6-17 years and ≥45 kg: "225 mg monthly").
Ajovy’s intended use is to lower monthly migraine days compared with placebo in people with episodic or chronic migraine.
14 Clinical Studies: Study 1 primary endpoint is mean change in monthly average number of migraine days; Study 2 includes migraine days as secondary endpoint; both are placebo-controlled.
In migraine-prevention studies, CGRP-targeting medicines like Ajovy are judged by whether patients see fewer monthly migraine days.
14 Clinical Studies: Study 1 primary efficacy endpoint is monthly average number of migraine days.
In migraine-prevention studies, CGRP-targeting medicines like Ajovy are judged by whether patients see fewer migraine attacks over time.
14 Clinical Studies uses "migraine days" as efficacy measures; the provided excerpt supports reduction in migraine days over time (endpoint change from baseline over the treatment period), though the label does not use the term "migraine attacks."
Not everyone responds to CGRP monoclonal antibodies.
Supported implicitly by responder analyses presented in 14 Clinical Studies (e.g., proportion reaching ≥50% reduction is not 100%).
Ajovy is used for migraine prevention in people with episodic migraine.
1 INDICATIONS AND USAGE: preventive treatment of migraine in adults; 14 Clinical Studies includes episodic migraine studies and pediatric episodic migraine (6-17 years).
Ajovy is used for migraine prevention in people with chronic migraine.
14 Clinical Studies includes a chronic migraine adult study (Study 2) with AJOVY preventive treatment vs placebo.
Unsupported Statements
Ajovy is designed to prevent migraine attacks.
The label excerpt provided does not use the phrasing "designed to prevent migraine attacks"; it states "indicated for... preventive treatment of migraine" (broader term than "attacks").
CGRP is a signaling molecule involved in migraine biology.
The provided label excerpt describes CGRP ligand binding/blocking mechanism but does not state that CGRP is a signaling molecule or describe migraine biology.
Many people look for benefits within the first couple of months of treatment.
The label excerpts include Study durations and some early timepoint (e.g., Study 2 change at 4 weeks after 1st dose), but do not support the general statement about patients "looking for benefits" within the first couple of months.
If Ajovy does not reduce migraine frequency meaningfully, clinicians may switch the preventive strategy.
The provided label excerpts do not describe treatment-switching guidance based on response.
If Ajovy does not reduce migraine frequency meaningfully, clinicians may try a different CGRP-targeting option.
No label excerpt provided supports switching to a different CGRP-targeting medicine.
If Ajovy does not reduce migraine frequency meaningfully, clinicians may add or adjust other migraine preventives.
No label excerpt provided supports adding/adjusting other preventives based on response.
Common side effects people report with Ajovy include injection-site reactions.
The provided label excerpts list only warnings/precautions and clinically significant adverse reactions (hypersensitivity, constipation with serious complications, hypertension, Raynaud’s phenomenon) and do not state injection-site reactions as common side effects.
Ajovy’s benefit and tolerability depend on factors such as baseline migraine frequency, triggers, other medications, and how consistently the injections are taken on schedule.
The provided label excerpts do not describe benefit/tolerability dependence on triggers, other medications, or injection adherence/schedule consistency.
Contradictions
Important Omissions
Pediatric indication details: episodic migraine in pediatric patients 6 to 17 years who weigh 45 kg or more; Ajovy not approved for pediatric patients weighing less than 45 kg due to lack of appropriate strength presentation.
Importance:
Moderate
Administration constraints and preparation instructions (e.g., subcutaneous use only; allow to sit at room temperature for 30 minutes; do not warm by heat source; do not use if at room temperature for 7 days or longer; do not co-administer at same site; injection site areas).
Importance:
Moderate
Missed dose instruction (administer as soon as possible; thereafter schedule from date of last dose).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes statements about "common side effects" (injection-site reactions) that are not supported by the provided label excerpts and includes unsourced generalizations about benefit/tolerability and response-guided treatment changes, which could mislead risk/management expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the supplied label excerpts (notably injection-site reactions as common side effects; general benefit timing; adherence/triggers factors; and response-based switching/adding other preventives).
Suggested Improvement
Limit statements to what the provided label excerpts support: (1) indication/prevention wording and pediatric weight criteria, (2) dosing regimens and administration as supported, (3) efficacy endpoints framed using label terms (e.g., migraine days) and placebo comparison where explicitly described, and (4) avoid naming specific common side effects or response-guided management actions unless present in the supplied label sections.